Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Johnson

Showing results (221-230 of 244) with videos related to

Pageof 25
Sort By:
BMJ (Clinical Research Ed.)|October 21, 2020
Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort studyAsh K Clift, Carol A C Coupland, Ruth H Keogh, et al.
Blood|June 11, 2015
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy resultsMichael L Wang, Kristie A Blum, Peter Martin, et al.
Leukemia & Lymphoma|April 10, 2020
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myelomaKatja Weisel, Meletios Dimopoulos, Philippe Moreau, et al.
NEJM Evidence|June 19, 2025
An Individualized Prediction Model for Early-Stage Classic Hodgkin's LymphomaAngie Mae Rodday, Andrew M Evens, Matthew J Maurer, et al.
Blood|March 31, 2021
KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomasJames Heward, Lola Konali, Annalisa D'Avola, et al.
The Lancet. Haematology|April 29, 2018
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trialMary Gleeson, Clare Peckitt, Ye Mong To, et al.
Nature Medicine|March 24, 2026
Implementation of the NHS England Lung Cancer Screening Programme over 5 yearsRichard W Lee, Arjun Nair, Haval Balata, et al.
JAMA|December 17, 2015
Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical TrialChristopher J Hawkey, Matthieu Allez, Miranda M Clark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2017
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab MonotherapyEmanuele Zucca, Annarita Conconi, Giovanni Martinelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2019
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell LymphomaAnas Younes, Laurie H Sehn, Peter Johnson, et al.
Pageof 25

Showing results (221-230 of 244) with videos related to

Sort By:
Pageof 25
BMJ (Clinical Research Ed.)|October 21, 2020
Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort studyAsh K Clift, Carol A C Coupland, Ruth H Keogh, et al.
Blood|June 11, 2015
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy resultsMichael L Wang, Kristie A Blum, Peter Martin, et al.
Leukemia & Lymphoma|April 10, 2020
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myelomaKatja Weisel, Meletios Dimopoulos, Philippe Moreau, et al.
NEJM Evidence|June 19, 2025
An Individualized Prediction Model for Early-Stage Classic Hodgkin's LymphomaAngie Mae Rodday, Andrew M Evens, Matthew J Maurer, et al.
Blood|March 31, 2021
KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomasJames Heward, Lola Konali, Annalisa D'Avola, et al.
The Lancet. Haematology|April 29, 2018
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trialMary Gleeson, Clare Peckitt, Ye Mong To, et al.
Nature Medicine|March 24, 2026
Implementation of the NHS England Lung Cancer Screening Programme over 5 yearsRichard W Lee, Arjun Nair, Haval Balata, et al.
JAMA|December 17, 2015
Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical TrialChristopher J Hawkey, Matthieu Allez, Miranda M Clark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2017
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab MonotherapyEmanuele Zucca, Annarita Conconi, Giovanni Martinelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2019
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell LymphomaAnas Younes, Laurie H Sehn, Peter Johnson, et al.
Pageof 25